EUVIMEDOdkrijte EUVIMED
Übersichtsarbeit

Optimizing Tacrolimus Target Trough Levels in Organ Transplantation Among Patients Living With HIV Receiving Antiretroviral Therapy

Uraiwan Akanit

Clinical Transplantation · 2026-04 · 40 (4)

DOI: 10.1111/ctr.70538 ↗

At a glance

Übersichtsarbeit in Clinical Transplantation, published online on 2026-04-06. Written by Uraiwan Akanit. Institution: Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Ubon Ratchathani, Thailand. Major MEDLINE topics: HIV Infections, Tacrolimus, Organ Transplantation, Immunosuppressive Agents. 30 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Solid organ transplantation (SOT) in patients living with HIV (PLWH) has transitioned from a relative contraindication to standard practice following the widespread use of effective antiretroviral therapy (ART). Although patient and graft survival increasingly parallel those of HIV‐negative recipients, optimizing immunosuppressive therapy—particularly tacrolimus—remains a major clinical challenge in this population.

Objectives

This review examines the mechanisms and clinical consequences of ART–tacrolimus drug–drug interactions, evaluates the role of therapeutic drug monitoring (TDM), and highlights emerging strategies to improve attainment of target tacrolimus trough levels in PLWH undergoing transplantation. Contents Tacrolimus has a narrow therapeutic index and is highly susceptible to cytochrome P450 3A4–mediated interactions with ART, especially protease inhibitor‐ and cobicistat‐based regimens. These interactions often necessitate extreme dose reductions, result in marked pharmacokinetic variability, and complicate maintenance of stable trough concentrations. Subtherapeutic exposure is associated with increased rejection risk, whereas supratherapeutic levels increase nephrotoxicity and infection. While integrase strand transfer inhibitor‐based regimens reduce interaction burden, many PLWH remain on boosted ART, underscoring the importance of intensive TDM. This review also discusses tacrolimus formulation choice as a modifiable factor, with growing evidence supporting liquid tacrolimus to enable micro‐dose titration and improve time in therapeutic range. Emerging pharmacometric approaches, including population pharmacokinetic modeling and Bayesian dosing, offer additional opportunities for precision immunosuppression.

Implications

Optimizing tacrolimus exposure—rather than HIV status itself—is central to transplant outcomes in PLWH. Integrating ART‐informed dosing, formulation flexibility, and advanced TDM strategies may reduce variability, improve graft outcomes, and inform future guideline development for this expanding transplant population.

Subjects

MeSH terms (MEDLINE)

HIV InfectionsTacrolimusOrgan TransplantationImmunosuppressive AgentsGraft RejectionDrug MonitoringAnti-HIV AgentsAnti-Retroviral AgentsHumansDrug InteractionsGraft SurvivalPrognosis

Author keywords

HIV infectionsantiretroviral therapydrug–drug interactionssolid organ transplantationtacrolimustherapeutic drug monitoring

Substances

TacrolimusImmunosuppressive AgentsAnti-HIV AgentsAnti-Retroviral Agents

Authors and institutions

  • Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Ubon Ratchathani, Thailand.
  • UBU Pharmacy Clinical Outcome Research (UPCOR) Group, Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Ubon Ratchathani, Thailand.

Cite

APA

Akanit, U. (2026). Optimizing Tacrolimus Target Trough Levels in Organ Transplantation Among Patients Living With HIV Receiving Antiretroviral Therapy. Clinical Transplantation, 40(4). https://doi.org/10.1111/ctr.70538

Vancouver

Akanit U. Optimizing Tacrolimus Target Trough Levels in Organ Transplantation Among Patients Living With HIV Receiving Antiretroviral Therapy. Clinical Transplantation. 2026;40(4). doi:10.1111/ctr.70538

BibTeX
@article{Akanit2026,
  author = {Akanit, Uraiwan},
  title = {Optimizing Tacrolimus Target Trough Levels in Organ Transplantation Among Patients Living With HIV Receiving Antiretroviral Therapy},
  journal = {Clinical Transplantation},
  year = {2026},
  volume = {40},
  number = {4},
  doi = {10.1111/ctr.70538}
}
Start for free →